Nuvelo and ARCA biopharma Advance Toward Completion... (ngs with the SEC are also available to t...)

Nuvelo and ARCA biopharma Advance Toward Completion of Merger

Date:12/1/2008

ngs with the SEC are also available to the public from commercial document-retrieval services and at SEC's website at http://www.sec.gov, and from Investor Relations at Nuvelo as described above.

This communication shall not constitute an offer to sell or the solicitation of an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Nuvelo, ARCA and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the stockholders of Nuvelo in connection with the merger transaction. Information regarding the special interests of these directors and executive officers in the merger transaction will be included in the proxy statement/prospectus of described above. Additional information regarding the directors and executive officers of Nuvelo is also included in Nuvelo's proxy statement for its 2008 Annual Meeting of Stockholders which was filed with the SEC on April 23, 2008 and its Annual Report on Form 10-K for the year ended December 31, 2007, which was filed with the SEC on March 12, 2008. These documents are available as described above.

SOURCE Nuvelo, Inc.; ARCA biopharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Nuvelo and ARCA biopharma Announce Merger Agreement Creating Late-Stage Cardiovascular Biotechnology Company
2. Nuvelo Initiates Phase 1 Clinical Trial of NU206 in Healthy Volunteers
3. Nuvelo Reports Second Quarter 2008 Financial Results
4. Nuvelo Reports First Quarter 2008 Financial Results and Updated Outlook for 2008
5. Therapure Biopharma Inc. Announces Manufacturing Agreement with Biomedical Frontiers Incorporated -- Contract will Support Phase II Trials for Thalassemia Treatment
6. MySignatureBook Certified Compliant With SAFE-BioPharma Digital Standard(TM)
7. Thomas K. Equels Elected to Hemispherx BioPharma, Inc. Board of Directors
8. Helix BioPharma Files Form 20-F Registration Statement With the U.S. Securities and Exchange Commission
9. InCode BioPharmaceutics Appoints New President and CEO
10. Med Discovery and Laborium Biopharma Sign a Bioprocess Development Partnership Agreement
11. Frost & Sullivan Awards Baxters BioPharma Solutions Business the 2008 North American Customer Service Leadership of the Year Award

Post Your Comments:

Nuvelo and ARCA biopharma Advance Toward Completion...(ngs with the SEC are also available to t...)